Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (CLVLY) Stock Overview
Explore Clinuvel Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
416M
P/E Ratio
17.78
EPS (TTM)
$0.49
ROE
0.19%
CLVLY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Clinuvel Pharmaceuticals Limited (CLVLY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 48.36, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $6.84.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.78 and a market capitalization of 416M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.